SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced new Phase 2 data for its AI-designed personalized…

Evaxion · PRESS-RELEASE filed Apr 17, 2026 at 15:10 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 17, 2026 at 15:10 ET

Evaxion announced new Phase 2 data for its AI-designed personalized cancer vaccine EVX-01, showing 86% of vaccine targets triggered a tumor-specific immune response, a rate higher than previously reported methods. The data, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the predictive power of its AI-Immunology™ platform.

  • 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, a record-high rate
  • Durable de novo T-cell responses observed, with 86% of responses being novel tumor-specific T cells
  • Positive correlation between AI-prediction scores and immune response magnitude confirms platform accuracy
  • Phase 2 trial in advanced melanoma combines EVX-01 with KEYTRUDA® (pembrolizumab), showing 75% Objective Response Rate at two years

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access